The best treatment for Barrett’s esophagus depends on whether the tissue shows signs of precancerous changes, called dysplasia. For most people with Barrett’s and no dysplasia, the standard approach is acid-suppressing medication combined with regular monitoring. When dysplasia is present, endoscopic procedures that destroy or remove the abnormal tissue become the primary treatment, with radiofrequency ablation clearing the changed tissue in about 78% of patients.
Why Dysplasia Status Drives the Treatment Plan
Barrett’s esophagus exists on a spectrum. At one end, the esophageal lining has changed but shows no precancerous features. At the other end, the tissue contains high-grade dysplasia, meaning cells that are well on their way to becoming cancerous. The annual risk of progressing to esophageal cancer is roughly 0.12% to 0.40% for Barrett’s without dysplasia, about 1% with low-grade dysplasia, and over 5% with high-grade dysplasia. Those numbers shape every treatment decision.
The American Gastroenterological Association strongly recommends endoscopic eradication therapy for people with high-grade dysplasia and conditionally recommends it for low-grade dysplasia. For Barrett’s without dysplasia, the recommendation is actually against endoscopic eradication, because the cancer risk is low enough that the potential downsides of treatment outweigh the benefits for most people. That doesn’t mean nothing is done. It means the treatment focus shifts to controlling acid reflux and watching for changes over time.
Acid-Suppressing Medication
Proton pump inhibitors (PPIs) are the foundation of Barrett’s management at every stage. These medications dramatically reduce stomach acid production, which limits ongoing damage to the esophageal lining. For Barrett’s patients, doctors typically prescribe a standard or double dose taken daily, sometimes split into two doses. The goal isn’t just symptom relief. Controlling acid exposure may slow or prevent the tissue from progressing toward cancer, though the evidence that any treatment fully prevents that progression remains limited.
If you have Barrett’s without dysplasia, PPIs paired with surveillance endoscopy every 3 to 5 years may be your entire treatment plan. This can feel underwhelming when you’re looking for a more definitive fix, but given the low annual cancer risk, this approach avoids unnecessary procedures while keeping close watch on any changes.
Radiofrequency Ablation
Radiofrequency ablation (RFA) is the first-line endoscopic treatment for Barrett’s with dysplasia. During the procedure, a small device is passed through an endoscope and uses heat energy to destroy the abnormal tissue. Over time, healthy esophageal lining regrows in its place.
A systematic review and meta-analysis found that RFA achieves complete eradication of the Barrett’s tissue in 78% of patients. It typically requires multiple sessions spaced a few months apart. The procedure is done on an outpatient basis, and most people go home the same day. You can expect some chest discomfort and difficulty swallowing for a few days afterward.
The main complication to be aware of is esophageal narrowing, or stricture. Studies report stricture rates ranging from about 5% to 17% depending on the extent of treatment. When strictures occur, they’re usually managed with balloon dilation, a procedure where the narrowed area is gently stretched open. Most patients need a handful of dilation sessions to resolve swallowing difficulties.
Endoscopic Mucosal Resection
When Barrett’s includes a visible raised area or nodule, endoscopic mucosal resection (EMR) is often the first step before ablation. Rather than destroying tissue with heat, EMR physically removes a section of the esophageal lining. This serves two purposes: it eliminates the suspicious area and provides a tissue sample for detailed examination under a microscope. That pathology information is critical for determining whether cancer cells have started to invade deeper layers.
EMR is recommended for high-grade dysplasia with visible lesions and for early-stage cancers that haven’t grown beyond the surface lining of the esophagus. Current guidelines favor combining focal EMR (removing the visible lesion) with ablation of the surrounding Barrett’s tissue, rather than using EMR alone to strip away the entire affected segment. This combination approach reduces the risk of complications while still addressing both the immediate threat and the surrounding at-risk tissue.
Cryotherapy as an Alternative
Cryotherapy uses extreme cold, typically liquid nitrogen at minus 196 degrees Celsius, to freeze and destroy Barrett’s tissue. It has emerged as an alternative for patients who don’t respond to radiofrequency ablation or who aren’t good candidates for it.
A meta-analysis comparing the two approaches across 627 patients found no significant difference in eradication rates or recurrence rates between cryotherapy and RFA. Adverse event rates were also comparable, with low numbers of strictures and no perforations reported in either group. This makes cryotherapy a reasonable option, particularly as a second-line treatment, though RFA remains the default choice because it has a longer track record and more supporting data.
Anti-Reflux Surgery
For people whose reflux isn’t well controlled by medication, or who prefer not to take PPIs indefinitely, anti-reflux surgery is worth considering. The most common procedure, called fundoplication, wraps the top of the stomach around the lower esophagus to reinforce the valve that prevents acid from flowing upward. In one study of 21 Barrett’s patients who underwent this surgery, reflux symptom scores dropped dramatically (from an average of 37.5 to 8.7 points), and acid exposure in the esophagus fell from 26.5% of a 24-hour period to just 2.1%.
The more intriguing finding: 38% of patients in that study showed complete loss of Barrett’s tissue on follow-up biopsies after a median of 3 years, and none developed dysplasia. Surgery controls both acid and bile reflux, which PPIs alone don’t fully address. That said, the evidence that surgery prevents progression to cancer is still thin. Anti-reflux surgery is best thought of as a way to achieve superior reflux control, with the possibility of tissue regression as a bonus rather than a guarantee.
Diet and Lifestyle Changes
Lifestyle modifications won’t reverse Barrett’s tissue, but they play a real role in reducing the acid reflux that drives ongoing damage. The most impactful change is timing: eating your last meal at least 3 hours before lying down significantly reduces nighttime reflux episodes. If you carry extra weight, losing it can reduce pressure on your stomach and lower esophagus, directly decreasing reflux.
Common trigger foods and drinks include citrus fruits, tomatoes, chocolate, coffee, alcohol, high-fat foods, mint, and spicy foods. Not everyone reacts to all of these, so it’s worth tracking which ones worsen your symptoms rather than eliminating everything at once. These changes work best alongside medication, not as a replacement for it.
What Ongoing Monitoring Looks Like
Regardless of which treatment you receive, Barrett’s esophagus requires long-term follow-up. Even after successful ablation, the abnormal tissue can recur. Surveillance endoscopy, where a camera is passed into your esophagus and tissue samples are taken, is the standard monitoring tool. The interval depends on your situation: people with no dysplasia are typically scoped every 3 to 5 years, while those who’ve had dysplasia treated may need annual or even more frequent checks initially.
For people with low-grade dysplasia, the treatment decision is genuinely personal. Guidelines support either endoscopic eradication or continued surveillance as reasonable choices. If you place a higher value on avoiding procedural risks and are comfortable with some uncertainty, surveillance is appropriate. If the idea of carrying precancerous tissue creates significant anxiety, treatment is equally justified. This is one of those situations where there’s no single right answer, and the best approach is the one that fits your risk tolerance and values.